Zenocutuzumab Antibody

SKU: orb1980496

Description

Zenocutuzumab (MCLA-128) is a bispecific antibody that inhibits the HER2/HER3 heterodimerization driven by NRG1 fusions. It is a research tool for studying NRG1-rearranged cancers, with utility demonstrated in both in vitro cell-based assays and in vivo xenograft models.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 1969309-56-5
• MW: 145.76 kDa
• Purity: 97.00%
• Target: EGFR,HER

Bioactivity

• In Vivo:
  Zenocutuzumab (2.5-25 mg/kg, intraperitoneal injection once weekly for 28 days) significantly reduced tumor growth and triggered tumor shrinkage and even regression.
• In Vitro:
  Zenocutuzumab (MCLA-128) (0.001-1000 nM, treated for 96 hours) inhibits the growth of lung and breast cancer cell lines. Zenocutuzumab (0.1-1000 nM, treated for 24 hours) induces apoptosis and triggers expression of markers of cell cycle arrest in lung and breast cancer cell lines by inhibiting phosphorylation of HER3 and AKT.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PB4188, PB 4188, MCLA128, MCLA-128, R040517, R 040517

Quick Database Links

Gene Symbol

EGFR,HER